H1N1 COUNTERMEASURES STRATEGY AND ... - PHE Home
H1N1 COUNTERMEASURES STRATEGY AND ... - PHE Home
H1N1 COUNTERMEASURES STRATEGY AND ... - PHE Home
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
NBSB Pandemic Influenza Working Group<br />
Detailed Report<br />
immediately following vaccination. These events were predominantly mild and transient.<br />
There was no escalation with the second dose, and compliance in receiving the second<br />
dose was above 95%.<br />
GSK agreed with CBER to query the data for a list of 120 immune-mediated diseases,<br />
called adverse events of special interest (AESIs). There were 16 AESIs in the H5 group<br />
and one among the controls (p > 0.2).<br />
GSK ran the same query on a pooled database of 11,721 subjects enrolled in five clinical<br />
trials of TIV conducted by GSK since 2004. Comparing the data demonstrates that the<br />
events reported more than once in the H5 group also appear in the TIV control group.<br />
These data provide no evidence for an association of any single event or of this class of<br />
events with the H5N1/AS03 vaccine.<br />
GSK’s safety summary supports a favorable risk-benefit profile for AS03-adjuvanted<br />
influenza vaccines and additional trial data are forthcoming. GSK has investigated two<br />
reports of asymptomatic autoimmune hepatitis. In case 1 (a child) the condition existed<br />
before vaccination and is in remission following treatment. In case 2 (an adult), the<br />
condition resolved spontaneously, and experts have cast doubt on the diagnosis.<br />
Since September 2008, GSK has been following a cohort of 43,000 elderly subjects<br />
vaccinated with TIV/AS03 or control, and their safety data are being reviewed by an<br />
Independent Data Monitoring Committee. GSK recently expanded the pooling of safety<br />
data to include recipients of any influenza vaccine with AS03. Results from this analysis<br />
of 20,500 adults exposed to AS03 will become available in July.<br />
The planned clinical development of <strong>H1N1</strong> vaccine with AS03 includes at least 13 trials<br />
of D- or Q-<strong>H1N1</strong> vaccine in the United States and Canada or in Europe, with over 5,000<br />
children and adults exposed to adjuvanted vaccine. The trials performed under an<br />
investigational new drug application (IND) are all randomized, blinded trials using<br />
antigen-only vaccine as a control. The adjuvanted vaccine will be evaluated<br />
simultaneously in children and adults. The trials will evaluate the benefit of the adjuvant<br />
in terms of dose-sparing, efficacy, and immunogenicity compared with antigen-only<br />
vaccine, and the two-dose, one-visit schedule. The possibility of interference between<br />
TIV and the pandemic vaccine will be evaluated when these products are coadministered<br />
or given sequentially. GSK will assess whether AS03 can overcome interference and will<br />
also confirm the equivalent immunogenicity between D and Q products. GSK will<br />
rapidly expand the safety database for this new vaccine. By December, the Company<br />
anticipates that 4,340 subjects will have been exposed to <strong>H1N1</strong>/AS03 in a GSK trial.<br />
Because the use of a novel adjuvant raises questions that can be addressed best by longterm<br />
follow up, GSK is discussing with HHS the need for a large, simple safety study<br />
involving, for instance, 40,000 persons who would be followed for up to two years after<br />
vaccination.<br />
19